Nusinersen — Membership Pricing

Other medications in Neurological

• Ocrelizumab
• Ofatumumab
• Oxcarbazepine
• Perampanel
• Phenobarbital
• Ponesimod
• Pramipexole
• Promethazine

About Nusinersen

Nusinersen, known by its brand name Spinraza, is a groundbreaking medication for Spinal Muscular Atrophy (SMA), a serious genetic disorder. This treatment has revolutionized care for many, but its cost can be substantial. TheDrugClub is dedicated to helping members navigate complex prescription pricing, aiming to provide paths to significant savings on vital medications like nusinersen.

Spinal Muscular Atrophy (SMA) is a rare, inherited neuromuscular disease characterized by progressive muscle weakness and loss due to the degeneration of motor neurons. Affecting individuals from infancy to adulthood, SMA can lead to severe physical disabilities, including difficulty breathing, swallowing, and moving. Nusinersen (Spinraza) represents a significant therapeutic advancement, offering hope and improved outcomes for patients living with SMA.

How Nusinersen Works

Nusinersen is an antisense oligonucleotide, a synthetic strand of genetic material designed to target a specific RNA molecule. In SMA, the body lacks sufficient amounts of a critical protein called Survival Motor Neuron (SMN) protein due to a genetic defect in the SMN1 gene. While most SMA patients have a 'backup' gene, SMN2, it typically produces a truncated, non-functional version of the SMN protein. Nusinersen works by modifying the splicing of the SMN2 gene's messenger RNA (mRNA) to increase the production of full-length, functional SMN protein. This increase in functional SMN protein helps preserve motor neurons, improve muscle function, and, in many cases, extend survival and enhance quality of life for individuals with SMA.

Understanding Typical Costs

As a highly specialized, life-changing medication, nusinersen carries a significant list price. The total cost can be very high, often reaching hundreds of thousands of dollars per year, particularly during the initial loading dose phase. These figures underscore the critical need for robust insurance coverage, patient assistance programs, and other financial support mechanisms. For most patients, direct out-of-pocket payment is not feasible, making access to comprehensive benefits paramount.

Maximizing Your Savings with TheDrugClub

Navigating the high cost of medications like nusinersen can be daunting, but TheDrugClub is here to help our members explore potential avenues for savings. For such specialized treatments, TheDrugClub can assist members in identifying and understanding their options for active-formulary benefits or discount pricing. While we cannot guarantee coverage or specific discounts for every individual, our program is designed to help you explore pathways that may reduce your financial burden.

Members can consult with our dedicated support team to understand how their specific plan benefits might apply. We can help you investigate whether nusinersen is on your plan's active formulary, which could significantly impact your out-

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Nusinersen is approved for (FDA label)

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: March 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Nusinersen (FDA label)

Injection: nusinersen is a clear and colorless solution supplied in single-dose vials in the following strengths: 12 mg/5 mL (2.4 mg/mL) 28 mg/5 mL (5.6 mg/mL) 50 mg/5 mL (10 mg/mL) Injection: 12 mg/5 mL (2.4 mg/mL) in a single-dose vial ( 3 ) Injection: 28 mg/5 mL (5.6 mg/mL) in a single-dose vial ( 3 ) Injection: 50 mg/5 mL (10 mg/mL) in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94. SPL document ID: cb572584-c0fd-42aa-b6d1-6dd8260028b5. Label effective date: March 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nusinersen (FDA label)

The following serious adverse reactions are described in detail in other sections of the labeling: Thrombocytopenia and Coagulation Abnormalities [see Warnings and Precautions ( 5.1 )] Renal Toxicity [see Warnings and Precautions ( 5.2 )] The most common adverse reactions that occurred in at least 20% of SPINRAZA-treated patients who received Low Dose Regimen and occurred at least 5% more frequently than in control patients were: lower respiratory infection and constipation in patients with infantile-onset SMA ( 6.1 ) pyrexia, headache, vomiting, and back pain in patients with later-onset SMA ( 6.1 ) The most common adverse reactions in at least 10% of SPINRAZA-treated patients who received High Dose Regimen and occurred at least 5% more frequently than in historic matched sham-control were: pneumonia, COVID-19, pneumonia aspiration, and malnutrition in patients with infantile-onset SMA ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biogen at 1-844-477-4672 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of SPINRAZA cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94. SPL document ID: cb572584-c0fd-42aa-b6d1-6dd8260028b5. Label effective date: March 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Nusinersen (FDA label)

Thrombocytopenia and Coagulation Abnormalities: Increased risk for bleeding complications; testing required at baseline and before each dose and as clinically needed ( 5.1 , 2.3 ) Renal Toxicity: Quantitative spot urine protein testing required at baseline and prior to each dose ( 5.2 , 2.3 ) 5.1 Thrombocytopenia and Coagulation Abnormalities Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. In the sham-controlled studies for patients with infantile-onset (Study 1) and later-onset (Study 2) SMA who received Low Dose Regimen [see Clinical Studies ( 14.1 , 14.2 )] , 24 of 146 (16%) SPINRAZA-treated patients with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 (14%) sham-controlled patients.

Source: FDA prescribing information (DailyMed). Set ID: dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94. SPL document ID: cb572584-c0fd-42aa-b6d1-6dd8260028b5. Label effective date: March 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.